
    
      It is a randomized open-label 4-sequence 4-period pharmacokinetic cross-over study. The
      objective of the pharmacokinetic study is to examine a drug-drug interaction of pantoprazole
      on the bioavailability mycophenolic acid administered as either mycophenolate mofetil
      (Cellcept(R) or mycophenolate Sodium; EC-MPS (Myfortic (R) in stable renal allograft
      recipients under maintenance immunosuppressive therapy (cyclosporine +/- low dose
      glucocorticoids).
    
  